medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2016, Number 2

<< Back Next >>

Acta Pediatr Mex 2016; 37 (2)

Arbovirus in Latin America

Arredondo-García JL, Méndez-Herrera A, Medina-Cortina H

Language: Spanish
References: 81
Page: 111-131
PDF size: 1428.57 Kb.


ABSTRACT

Diseases produced by arboviruses are a major worldwide problem due to the fact that the surveillance and prevention of them implies the surveillance of vectors, which makes it very difficult to control them, and almost impossible to avoid their expansion to any tropical or subtropical country, and even some temperate regions. Globally, dengue is the most common arboviral disease, with 40% of the world population living in areas with dengue virus transmission. Of the estimated 390 million infections and 100 million cases annually, a small proportion of these cases progress to severe dengue. Approximately one in 2,000 dengue cases result in death. However, the case-fatality rate of patients with severe dengue can be reduced from almost 10% to less than 0.1% by the timing and quality of clinical care that patients receive. This, coupled with the recent and quick spread of Chikungunya virus and the outbreak of Zika virus in Latin American countries including Mexico, makes it necessary the medical update and review of bibliography concerning the prevention, control and management of arboviral-caused diseases. Therefore we present a review of the most recent literature on arboviral diseases in Latin America.


REFERENCES

  1. World Health Organization: Arbovirus and human disease. WHO Technical Report Series. (Geneva).1967;369:1-84.

  2. Division of Vector-Borne Diseases: Vector-Borne threats and what we do about them. Centers for Disease Control and Prevention. (Atlanta) 2014. [Última actualización: 31 de julio del 2014] [ Acceso: 11 de noviembre del 2015] Disponible en: http://www.cdc.gov/ncezid/dvbd/about. html

  3. Navarrete-Espinosa J, Gómez-Dantés H: Arbovirus causales de fiebre hemorrágico en pacientes del Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc. 2006;44 (4):347-353.

  4. Normile D. Surprising new dengue virus throws a spanner in disease control efforts. Science. 2013;342:415.

  5. van den Hurk AF, Hall-Mendelin S, Pyke AT: Vector competence of Australian mosquitoes for chikungunya virus. Vector-Borne and Zoonotic Diseases. June 2010, 10(5): 489-495. doi:10.1089/vbz.2009.0106.

  6. Fajardo-Dolci G, Melijem-Moctezuma J, Vicente-González E, et al. El dengue en México. Rev Med Inst Mex Seguro Soc. 2012;50 (6):631-39.

  7. Thirión-Icaza J: El mosquito Aedes aegypti y el dengue en México [Monografía de Internet]. México: Bayer Environmental Science. 2010. [Acceso 15 de noviembre del 2015]. Disponible en: http://www.slipe.org/pdf/ libro_jthpdf.pdf

  8. Villegas-Trejo A, Che-Mendoza A, González-Fernández M: Control enfocado de Aedes aegypti en localidades de alto riesgo de transmisión de Dengue en Morelos, México. Salud Pública Méx. 2011;53(2):141-51.

  9. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108: 717–725. doi: 10.1016/s0092- 8674(02)00660-8.

  10. Villar L, Dayan GH, Arredondo-García JL, et al: Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372:113-23. DOI: 10.1056/NEJMoa1411037

  11. Holmes EC. Molecular epidemiology and evolution of emerging infectious diseases. Brit Mel Bull.1998;54:533-543.

  12. Da Silva Voorham J.M. A possible fifth dengue virus serotype. Ned. Tijdschr. Geneeskd.2014;158:A7946.

  13. Vasilakis N, Durbin AP, da Rosa AP: Antigenic relationships between sylvatic and endemic dengue viruses. Am J Trop Hyg. 2008;79(1):128-32.

  14. AngelRMd, Valle JR-d. Dengue Vaccines: Strongly Sought but Not a Reality Just Yet. PLoS Pathog. 2013;9(10): e1003551.

  15. Uribarren-Berrueta T: Dengue, fiebre Chikungunya y otros arbovirus. Recursos en virología. México (2015). Acceso: 15 de noviembre del 2015. Disponible en: http://www.facmed. unam.mx/deptos/microbiologia/virologia/dengue.html

  16. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enchancement of infections upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free-radical and proinflammatory cytokine production, in THP-1 cells. Journal of General Virology (2007), 88, 365-375.

  17. Guy B, Jackson N: Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nature Reviews. France (2015). doi:10.1038/nrmicro.2015.2

  18. Pan American Heatlh Organization: Number of Reported Cases of Dengue and Severe Dengue in the Americas, by Country – December 1, 2015 (EW 45). Annual Cases Reported of Dengue (Atlanta) 2015. Accesado: 3 de Diciembre del 2015. Disponible en: http://www.paho.org/hq/index. php?option=com_topics&view=rdmore&cid=6290&Itemi d=40734&lang=en

  19. Dirección General de Epidemiología: Panorama Epidemiológico de Fiebre por Dengue y Fiebre Hemorrágica por Dengue. Secretaría de Salud (México) 2015. Acceso: el 3 de diciembre del 2015. Disponible en: http://www.epidemiologia.salud. gob.mx/dgae/panodengue/intd_dengue.html

  20. Zambrano B, San Martin JL: Epidemiology of Dengue in Latin America. Journal of the Pediatric Infectious Diseases Society. 2015; Vol.3, No. 3, pp. 181-2

  21. Picollo-Oliveira JF, Burdmann EA: Dengue-associated acute kidney injury. Clinical Kidney Journal. 2015; vol. 8, no. 6, 681-685.

  22. de Souza LJ, Pessanha LB, Mansur LC, et al: Comparison of clinical and laboratory characteristics between children and adults with dengue. Braz J Infect Dis. 2013; 17 (1): 27-31.

  23. Kittigul L, Pitakarnjanakul P, Sujirarat D, et al. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol, 2007;39:76–81.

  24. Libraty DH, Wang P, Guo Z, et al: The pattern of adipose tissue accumulation during early infancy provides an environment for the development of dengue hemorrhagic fever. PLoS Negl Trop Dis. 2015; 9(12): e0004267. doi:10.1371/ journal.pntd.0004267

  25. Aggarwal A, Kumar P, Faridi MM: Neurological manifestation as presenting feature of dengue infection. J Pediatr Neurosci, 2015; 10 (1): 76-7.

  26. Babaliche P, DOshi D: Catching Dengue Early: Clinical Features and Laboratory Markers of Dengue Virus Infection. J Assoc Physicians( India). 2015; 63(5): 38-41.

  27. Unnikrishnan R, Faizal BP, Vijayakumar P: Clinical and laboratory profile of dengue in the elderly. J Family Med Prim Care. 2015; 4(3): 369-72.

  28. Parkash O, Shueb RH: Diagnosis of dengue infection using conventional and biosensor based techniques. Viruses. 2015; 7(10): 5410-27.

  29. Simmons CP, McPherson K, Van Vinh Chau N, et al: Recent advances in dengue pathogenesis and clinical management. Vaccine. 2015; 33(50): 7061-8.

  30. Wongsa A: Fluid and hemodynamic management in severe dengue. Southeast Asian J Trop Med Public Health. 2015; 46 Suppl 1: 123-7

  31. Medeiros DN, Ferrani JF, Delgado AF, et al: Colloids for the initial management of severe sepsis and septic shock in pediatric patients: a systematic review. Pediatr Emerg Care. 2015; 31(11): 11-6.

  32. Villareal VA, Rodgers MA, Costello DA, et al: Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antiviral Res. 2015; 124: 110-21.

  33. Whitehorn J, Nquyen CV, Khanh LP, et al: Lovastatin for the treatmet of adult patients with dengue: a randomised, double-blind, placebo-controlled trial. Clin Infect Dis. 2015. pii: civ949. [Epub ahead of print]

  34. Rattanaburee T, Junking M, Panya A, et al: Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A. Antiviral Res. 2015; 124:83-92.

  35. Choy MM, Zhang SL, Costa VV, et al: Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection. PLoS Negl Trop Dis. 2015; 9(11): e0004058. doi:10.1371/journal.pntd.0004058

  36. Zhang F, Kramer CV: Corticosteroids for dengue infection. Cochrane Database Syst Rev. 2014; 1;7:CD003488. doi: 10.1002/14651858.CD003488.pub3.

  37. Kurukularatne C, Dimatatac F, Teo DL, et al: When less is more: can we abandon prophylactic platelet transfusion in dengue fever? Ann Acad Med Singapore. 2011; 40:539–45.

  38. COFEPRIS: México aprueba la primera vacuna contra el virus del dengue a nivel mundial. Secretaría de Salud (México) 2015. Acceso: 11 de diciembre del 2015. Disponible en: http://www.cofepris.gob.mx/Documents/NotasPrincipales/ 09122015.pdf

  39. Organización Panamericana de la Salud: Preparación y respuesta ante la eventual introducción del virus chikungunya en las Américas. Washington, D.C.2011; 1: 1-148.

  40. Martínez-Sánchez A, Martínez-Ramos EB, Chávez-Angeles MG: Panorama situacional de México ante la pandemia del virus chikunguña. Rev Med Inst Mex Seguro Soc. 2015; 53(2): 200-5.

  41. Sahadeo N, Mohammed H, Allicock OM, et al: Molecular characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015; 9(11): doi: 10.1371/journal.pntd.0004199. eCollection 2015

  42. Caglioti C, Lalle E, Castilletti C: Chikungunya virus infection: an overview. New Microbiologica. 2013; 36(3): 211-27.

  43. Markedian SK, Roberts AL: Diagnostic options and challengues for dengue and chikungunya viruses. BioMed Research International. 2015; vol. 2015, Article ID 834371, 8 pages. doi:10.1155/2015/834371

  44. Courderc T, Lecuit M: Chikungunya virus pathogenesis: From bedside to bench. Antiviral Res. 2015; 121: 120-31

  45. Pan American Heatlh Organization: Number of Reported Cases of Chikungunya in the Americas, by Country – December 11, 2015 (EW 49). Annual Cases Reported of Chikungunya (Atlanta) 2015. Accesado: 15 de Diciembre del 2015. Disponible en:http://www.paho.org/hq/index.php?option=com_ docman&task=doc_download&Itemid=&gid=32576&lang=en

  46. Balmaseda A, Gordon A, Gresh L: Clinical attack rate of chikungunya in a cohort of Nicaraguan children. Am J Trop Med Hyg. 2015; doi: 10.4269/ajtmh.15-0413

  47. Carter JR, Taylor S, Fraser TS: Supression of the arboviruses dengue and chikungunya using a dual-acting group-I intron coupled with conditional expression of the Bax C-terminal domain. PLoS ONE. 2015; 10(11): e0139899. doi:10.1371/ journal.pone.0139899

  48. Halstead SB: A re-examination of the history of etiologic confusion between dengue and chikungunya. PLoS Negl Trop Dis. 2015; 9(11): e0004101. doi:10.1371/journal. pntd.0004101

  49. Bhatia MS, Gauam P, Jhanjee A: Psychiatric morbidity in patients with chikungunya fever: first report from India. J Clin Diagn Res. 2015; 9(19: VC01-VC03.

  50. Staples JE, Breiman RF, Powers AM: Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009; 49(6): 942-8

  51. Ribéra A, Degasne I, Jaffar Bandjee MC, et al: Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations. Med Trop (Mars). 2012; 72 Spec No:83-5.

  52. Arroyo-Ávila M, Vilá LM: Rheumatic manifestations in patients with chikungunya infection. P R Health Sci J. 2015;34(2):71-7.

  53. Lam s, Nyo M, Phuektes P: A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against chikungunya virus pathogenesis. MAbs. 2015;7(6):1178-94.

  54. Fernández-Salas I, Danis-Lozano R, Casas-Martínez M: Historical inability to control Aedesaegipty as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral Research. 2015;124:30-42.

  55. Schwameis M, Buchtele N, Wadowski PP: Chikungunya vaccines in development. Hum Vaccin Immunother. 2015. 10:0. [Epub ahead of print]

  56. Ioos S, Mallet HP, LeparcGoffart I, et al: Current Zika virus epidemiology and recent epidemics. Médecine et Maladies Infectieuses. 2014;44(11):302-7.

  57. Comité Nacional para la Vigilancia Epidemiológica: Situación epidemiológica de infección por virus Zika en América. Secretaría de Salud. 2015. [Acceso: 15 de diciembre del 2015]. Disponible en: http://www.epidemiologia. salud.gob.mx/doctos/avisos/2015/zika/Aviso%20 Epidemiol%C3%B3gico-ZIKA%20VIRUS221015.pdf

  58. Comité Nacional para la Vigilancia Epidemiológica: Infección por virus Zika, síndrome neurológico y anomalías congénitas. Secretaría de Salud. 2015. [Acceso: 15 de diciembre del 2015]. Disponible en: http://www. epidemiologia.salud.gob.mx/doctos/avisos/2015/zika/ Aviso_ZIKA_SX_NEUROLOGICO_101215.pdf

  59. Dirección General de Epidemiología: Boletín Epidemiológico. Secretaría de Salud. 2016; 6(33): 35. [Acceso: 24 de febrero del 2016]. Disponible en: http://www.epidemiologia. salud.gob.mx/dgae/boletin/intd_boletin.html

  60. Cardoso CW, Paploski IAD, Kikuti Mariana, et al: Outbreak of exanthematous illness associated with Zika, Chikungunya and Dengue viruses, Salvador, Brazil. Emerg Infect Dis. 2015; 21(12): 2274-6

  61. Zanluca C, Campos-Andrade de Melo V, Pamplona-Mosimann AL, et al: First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz. 2015; 110(4):569-72.

  62. Gatherer D, Kohl A: Zika virus: a previously slow pandemic spreads rapidly through the Americas. Journal of General Virology. 2016; 97: 269-73.

  63. Brisola-Marcondes C, Freire de Melo-Ximenes MF: Zika virus in Brazil and the danger of infestation by Aedes (Stegomyia) mosquitoes. Rev Soc Bras Med Trop. 2015; Epub ahead of print: http://dx.doi.org/10.1590/0037- 8682-0220-2015.

  64. Besnard M, Lastère S, Teissier A, et al: Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill. 2014;19(13).

  65. Musso D, Roche C, Robin E, et al: Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015; 21(2): 359-61.

  66. Henry R: Etymologia: Zika virus. Emerg Infect Dis. 2014; 20(6): 1090

  67. Tognarelli J, Ulloa S, Villagra E, et al: A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. Archives of Virology. 2016; 161(3): 665-8.

  68. Hennessey M, Fischer M, Staples JE: Zika virus spreads to new areas-region of the Americas, May 2015-January 2016. Morb Mortal Wkly Rep. 2016; 65(3): 55-8.

  69. Gulland A: WHO urges countries in dengue belt to look out for Zika. BMJ. 2016;352:595.

  70. Martines RB, Bhatnagar J, Keating MK, et al: Notes from the field: Evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses. Morb Mortal Wkly Rep. 2016; 65: 159-60.

  71. Mlakar J, Korva M, Tul N, et al: Zika virus associated with microcephaly. N Engl J Med. 2016: DOI: 10.1056/NEJMoa1600651

  72. Jampol LM, Goldstein DA: Zika virus infection and the eye. JAMA Ophtalmol. 2016: doi:10.1001/jamaophthalmol. 2016.0284

  73. de Paula-Freitas B, de Oliveira-Dias JR, Prazeres J: Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in Salvador, Brazil. JAMA Ophtalmol. 2016: doi: 10.1001/jamaophthalmol. 2016.0267

  74. Calvet G, Aquiar RS, Melo AS, et al: Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis. 2016: doi: 10.1016/S1473-3099(16)00095-5

  75. Musso D, Baud D: Zika virus: time to move from case reports to case control. Lancet Infect Dis. 2016: doi:10.1016/ S1473-3099(16)00096-7

  76. Oliveira-Melo AS, Malinger G, Ximenes R, et al: Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg?. Ultrasound Obstet Gynecol. 2016; 47(1): 6-7.

  77. Heymann DL, Hodgson A, Alpha-Sall Amadou, et al: Zika virus and microcephaly: why is this situation a PHEIC?. Lancet. 2016; 387(10020): 719-21.

  78. Curtis Z, Matzen K, Neira-Oviedo M: Assessment of the impact of potential tetracycline exposure on the phenotype of Aedes aegypti OX513A: implications for field use. PLoS Negl Trop Dis. 2015: doi: 10.1371/journal. pntd.0003999

  79. Santiago FW, Halsey ES, SIles C, et al: Long-Term artralgia after Mayaro virus infection correlates with sustaines pro-inflammatory cytokine response.PLoS Negl Trop Dis: 9(10):e0004104. doi:10.1371/journal.pntd.0004104

  80. Napolea-Pego P, Gomes LP, Provance-Jr DW, et al: Mayaro Virus Disease. J Hum Retrovirol(2008) 1(3): 00018. DOI:10.15406/jhvrv.2014.01.00018

  81. Subsecretaría de prevención y promoción de la salud: Lista actualizada de productos recomendados por el CENAPRECE para el combate de insectos vectores de enfermedades a partir del 2015. Secretaría de Salud. [Acceso: 20 de diciembre del 2015]. Disponible en: http://www.cenaprece.salud. gob.mx/programas/interior/vectores/descargas/pdf/ ListaActualizadaInsumosRecomendadosCENAPRECE2015. pdf




2020     |     www.medigraphic.com